{"entity":{"id":"nct06692166","kind":"trial","name":"A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer","aka":[],"tldr":"A phase 3 trial of 9MW2821 in cervical cancer, run by Mabwell (Shanghai) Bioscience Co., Ltd., now recruiting.","summary":"A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer is a phase 3 interventional study registered as NCT06692166 by Mabwell (Shanghai) Bioscience Co., Ltd., with 420 participants planned, started 2024-09-10 and due to reach its primary completion in 2027-12-09. Interventions recorded: 9MW2821 and Chemotherapy.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06692166","url":"https://clinicaltrials.gov/study/NCT06692166"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cervical"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06692166","phase":"3","setting":"A Randomized, Open-label, Phase 3 Study to Evaluate 9MW2821 vs Treatment of Physician's Choice in Subjects With Recurrent or Metastatic Cervical Cancer Who Progressed on or After Platinum-based Chemotherapy","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","enrolled":420,"outcomes":[]},"route":"/trials/nct06692166/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"}]}}